We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ABIVAX

News List

Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients pharmatimes
May 27, 2021
French biotech company Abivax has revealed positive topline results from a Phase IIb study of its investigational oral drug candidate ABX464 in ulcerative colitis (UC) patients.
Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S. firstwordpharma
March 06, 2019
Abivax (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biopharmaceutical company harnessing the immune system to develop novel treatments for patients with inflammatory/autoimmune, and viral diseases and cancer...